# Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)

> **NCT01092091** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bio-Cancer Treatment International Limited** · enrollment: 20 (actual)

## Conditions studied

- Neoplasm
- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Pegylated Recombinant Human Arginase I

## Key facts

- **NCT ID:** NCT01092091
- **Lead sponsor:** Bio-Cancer Treatment International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-03-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01092091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01092091, "Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01092091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*